The ultimate goal of Oncotarget is to end all diseases in life. The weekly updates of scholarly reviewed scientific journals enables the science community to stay updated on the latest findings in the field of science. The website is a true opportunity for anyone who wants to have contributory effects in a field that is ever so changing and challenging our minds as a total human race.
The website of Oncotarget has essentially been created to allow science enthusiasts to have a resource to go to for finding the best researched items in the fields of science and oncology in current times. Oncotarget is published by Impact Journals and is updated weekly so that its visitors can have an updated set of current events resources so that they may be able to potentially utilize them for their own research and possibly make contributions to the scientific community. Such efforts made by various different science enthusiasts are what enables to advance as a society and overall human race in scientific advancements and discoveries. It is the work of individuals and groups as a whole that enables us to treat diseases, cure the ill, rehabilitate the injured, advance in technology at rates that we have never experienced before. The world of science is something that most people may never be able to grasp and a much smaller percentage of the population will never be able to grasp even half of what science has taught us or is teaching us. There is simply too many elements of scientific elements and knowledge for someone to have a full grasp of science in one lifetime, however, this does not mean that we cannot conduct our own sets of researching so that we may have opportunities of contributing to science so that future generations can continue to finish what has been started. This is how we will evolve as a human race and Oncotarget is a website that wants to be seen as a tremendous contributor in the field as well. Visit the website to learn more about what it is doing in the fields of science and oncology.
Follow Oncotarget journal on Twitter.